Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIA or IIB hyperlipoproteinemia

Journal of Cardiovascular Pharmacology

Volumn 27, Issue 4, 1996, Pages 563-570

  Steinmetz, Armin ^a   Schwartz, Thomas ^b   Hehnke, Uwe ^b   Kaffarnik, Hans ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b Knoll AG   (Germany)

Author keywords

Fenofibrate; Micronized; Primary hyperlipidemia; Simvastatin; Treatment

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; FENOFIBRATE; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROBUCOL; SIMVASTATIN; TRIACYLGLYCEROL; URIC ACID;

ADULT; ARTICLE; BLOOD CHEMISTRY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERLIPOPROTEINEMIA TYPE 1; HYPERLIPOPROTEINEMIA TYPE 2; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROLOGIC DISEASE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LOVASTATIN; MALE; MIDDLE AGED; PROCETOFEN; SIMVASTATIN; TRIGLYCERIDES;

EID: 0029984528     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199604000-00016     Document Type: Article

References (36)

1. LaRosa JC. Cholesterol lowering, low cholesterol, and mortality. Am J Cardiol 1993;72:776-86.
2. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? Br Med J 1994;308: 367-72.
3. Holme I. Relation of coronary heart disease incidence and total mortality to plasma cholesterol reduction in randomised trials: use of meta analysis. Br Heart J 1993;69(suppl 1):42-7.
4. The Scandinavien Simvastatin Survival Study group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavien Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
5. Blankenhorn DH, Hodis HN. Arterial imaging and atherosclerosis reversal. Arterioscler Thromb 1994;14:177-92.
6. Brown WV, Dujovne CA, Farquhar JW, et al. Effects of fenofibrate on plasma lipids: double-blind, multicenter study in patients with type II a or II b hyperlipidemia. Atherosclerosis 1986;6:670-8.
7. Blane GF, Bogaievski Y, Bonnefous F. Fenofibrate: influence on circulating lipids and side-effects in medium and long-term clinical use. In: Pharmacological control of hyperlipidaemia. J. R. Prous Science Publishers, Barcelona, 1986: 187-216.
8. Seidehamel RJ. Fenofibrate in type IV and type V hyperlipoproteinemia. Cardiology 1989;76(suppl 1):23-32.
9. Blane GF. Review of European clinical experience with fenofibrate. Cardiology 1989;76(suppl 1):1-13.
10. Knopp RH. Review of the effects of fenofibrate on lipoproteins, apoproteins, and bile saturation: US studies. Cardiology 1989,76(suppl 1):14-22.
11. Fievet C, Douste-Blazy P, Drouin P, et al. Effects of fenofibrate on apolipoprotein β-containing particles in patients with hyperlipoproteinemia. Curr Ther Res 1990;47:353-66.
12. Bard J-M, Parra H-J, Camare R, et al. A multicenter comparison of the effects of simvastatin and fenofibrate therapy in severe primary hypercholesterolemia, with particular emphasis on lipoproteins defined by their apolipoprotein composition. Metabolism 1992;5:498-503.
13. Farnier M, Bonnefous F, Debbas N, Irvine A. Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type II a or II b hyperlipidemia. Arch Intern Med 1994;154:441-9.
14. Rubba P, Falanga A, Postiglione A, Patti L, Mancini M. Increase in lipoprotein lipase activity after fenofibrate treatment in primary hyperlipoproteinemia. Clin Ther Cardiovasc 1982;2:177-9.
15. Heller F, Harvengt C. Effects of clofibrate, benzafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects. Eur J Clin Pharmacol 1983;25:57-63.
16. Chazan JB. New developments concerning the mode of action of fenofibrate. In: Carlson LA, Olsson AG, eds. Treatment of hyperlipoproteinemia. New York: Raven Press, 1984:171-4.
17. Schneider A, Stange EF, Ditschuneit HH, Ditschuneit H. Fenofibrate treatment inhibits HMG-CoA reductase activity in mononuclear cells from hyperlipoproteinemic patients. Atherosclerosis 1985;56:257-62.
18. Walker JF. Simvastatin: the clinical profile. Am J Med 1989; 87(suppl 4A):445-65.
19. Boccuzzi SJ, Keegan ME, Hirsch L, Shapiro DR, Plotkin DJ, Mitchel YB. Long-term safety and efficacy profile of simvastatin. Am J Cardiol 1991;68:1127-31.
20. Bilheimer DW, Grundy SM, Brown MS, Goldstein JL. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc Natl Acad Sci USA 1983;80:4124-8.
21. Mol MJ, Erkelens DW, Gevers Leuven JA, Schouten JA, Stalenhoef AFH. Simvastatin (MK-733): a potent cholesterol synthesis inhibitor in heterozygous familial hypercholesterolaemia. Atherosclerosis 1988;69:131-7.
22. Bard JM, Luc G, Douste-Blazy P, et al. Effect of simvastatin on plasma lipids, apolipoproteins, and lipoprotein particles in patients with primary hypercholesterolaemia. Eur J Clin Pharmacol 1989;37:545-50.
23. French JK, White HD, Greaves SC. Simvastatin therapy for hypercholesterolaemia in patients with coronary heart disease. NZ Med J 1990;103:41-3.
24. Tood PA, Goa KL. Simvastatin: a review of its pharmacological properties and therapeutic potential in hypercholesterolemia. Drugs 1990;40:583-607.
25. Stohler R, Keller U, Riesen WF. Effects of simvastatin and fenofibrate on serum lipoproteins and apolipoproteins in primary hypercholesterolemia. Eur J Clin Pharmacol 1989;37: 199-203.
26. Ziegler O, Drouin P. Safety, tolerability and efficacy of simvastatin and fenofibrate: a multicenter study. Cardiology 1990;77(suppl 4):50-7.
27. Parra H, Fievet C, Boniface B, Bertrand M, Duthilleul P, Fruchart JC. Lipoproteins, apolipoproteins, and coronary artery disease assessed by coronary arteriography. In: De Gennes JL, Polonovski J, Paoletti R, etds. Latent dyslipoproteinemias and atherosclerosis. New York: Raven Press, 1984:187-97.
28. Gotto AM Jr, Farmer JA. Risk factors for coronary artery disease In Braunwald E, ed. Heart disease: a textbook of cardiovascular medicine, 3rd ed., vol. 2. Philadelphia: W.B. Saunders, 1988:1153-90.
29. Brown GJ, Albers JK, Fisher D, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;19:1289-98.
30. Hahmann H, Bunte T, Hellwig N, et al. Progression and regression of minor coronary arterial narrowings by quantitative angiography after fenofibrate therapy. Am J Cardiol 1991;67:957-61.
31. Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglycerides and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study - implications for treatment. Circulation 1992;85:37-45.
32. Rubin EM, Krauss EM, Spengler EA, Verstuyft JG, Clift SM. Inhibition of early atherosclerosis in transgenic mice by human apolipoprotein AI. Nature 1991;353:265-7.
33. Assmann G, Schulte H. High density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol 1992;70:733-7.
34. Huttunen JK, Manninen V. Mänttäri M, et al. The Helsinki Heart Study: central findings and clinical implications. Ann Med 1991;23:155-9.
35. Ernst E. Plasma fibrinogen: an independent cardiovascular risk factor. J Intern Med 1990;227:365-72.
36. Leschke M, Höffken H, Schmidtsdorf A, Egbring R, Josef K, Strauer BE. Einfluß von Fenofibrat auf Fibrinogenkonzentration und Blutfluidität. Konsequenzen für die myokardiale Mikrozirkulation bei der koronaren Herzerkrankung? Dtsch Med Wochenschr 1989;113:939-44.